Literature DB >> 12968678

Abnormalities in bone mineral density and bone histology in thalassemia.

Somnuek Domrongkitchaiporn1, Vorachai Sirikulchayanonta, Pantep Angchaisuksiri, Wasana Stitchantrakul, Chavasak Kanokkantapong, Rajata Rajatanavin.   

Abstract

UNLABELLED: This study demonstrated that there was extensive iron staining on trabecular surface and marked reduction in trabecular bone volume without significant alteration in bone formation and bone resorption rates as well as significant reduction in bone mineral density in 18 thalassemic patients. Serum IGF-I was reduced and may modulate the reduction of bone mass.
INTRODUCTION: Bone histomorphometric studies in thalassemia to show alterations in bone histology and their relationship to biochemical parameters are very limited. Therefore, this study was systematically conducted to determine the alterations in thalassemia patients.
METHODS: Serum biochemical parameters, trans-iliac crest bone biopsy, and determination of bone mineral density of femur and lumbar spine were done in 18 thalassemic patients (10 females and 8 males).
RESULTS: Serum osteocalcin, carboxy terminal teleopeptide fragment of type I collagen, and parathyroid hormone levels were within normal limits, but serum 25(OH) vitamin D (19.3 +/- 1.6 ng/ml) and 1,25(OH)2 vitamin D (33.77 +/- 1.51 pg/ml) levels were decreased. Serum insulin-like growth factor I (IGF-I; 145.2 +/- 20 ng/ml) was suppressed, whereas serum ferritin (1366.6 +/- 253.9 ng/ml) was markedly elevated. Reduced bone mineral density was found in all studied areas. Trabecular bone volume was significantly decreased (16.65 +/- 1.12%), whereas bone formation rate, eroded surface, and other bone histomorphometric parameters were within normal limits. The trabecular bone volume varied significantly with bone mineral density of total femur (r = 0.48, p = 0.04). There was an extensive stainable iron surface on the mineral front (9-60%). Significant correlation between serum IGF-I, serum ferritin, stainable iron surface, and bone mineral density, lumbar spine, and total femur were found. Serum IGF-I correlated with trabecular bone volume (r = 0.6, p = 0.03), inversely with both serum ferritin level (r = -0.6, p < 0.01), and inversely with stainable iron surface (r = -0.53, p = 0.02). Multiple regression analysis demonstrated that IGF-I was the only independent variable that determined bone mineral density of lumbar spine and total femur.
CONCLUSION: Low bone mineral density and reduced trabecular bone volume with extensive iron deposition are the predominant findings in thalassemic patients. There was no evidence of increased bone resorption or mineralization defect. A reduction in circulatory IGF-I may modulate the reduction of bone mass.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12968678     DOI: 10.1359/jbmr.2003.18.9.1682

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  18 in total

1.  Changes in bone microarchitecture and biomechanical properties in the th3 thalassemia mouse are associated with decreased bone turnover and occur during the period of bone accrual.

Authors:  Maria G Vogiatzi; Jaime Tsay; Kostas Verdelis; Stefano Rivella; Robert W Grady; Stephen Doty; Patricia J Giardina; Adele L Boskey
Journal:  Calcif Tissue Int       Date:  2010-05-07       Impact factor: 4.333

2.  Impaired bone formation and osteopenia in heterozygous β(IVSII-654) knockin thalassemic mice.

Authors:  Kanogwun Thongchote; Saovaros Svasti; Mayurachat Sa-ardrit; Nateetip Krishnamra; Suthat Fucharoen; Narattaphol Charoenphandhu
Journal:  Histochem Cell Biol       Date:  2011-06-09       Impact factor: 4.304

3.  Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover.

Authors:  Ellen B Fung; Elliott P Vichinsky; Janet L Kwiatkowski; James Huang; Laura K Bachrach; Aenor J Sawyer; Babette S Zemel
Journal:  Bone       Date:  2011-04-05       Impact factor: 4.398

4.  Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia.

Authors:  Nicholas G Angelopoulos; Anastasia Goula; Grigorios Rombopoulos; Victoria Kaltzidou; Eugenia Katounda; Dimitrios Kaltsas; George Tolis
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

5.  Evaluation of osteopathy in thalassemia by bone mineral densitometry and biochemical indices.

Authors:  Rashid Merchant; Amish Udani; Vipla Puri; Valentina D'cruz; Deepak Patkar; Aarti Karkera
Journal:  Indian J Pediatr       Date:  2010-08-25       Impact factor: 1.967

Review 6.  Osteoporosis in children and adolescents: etiology and management.

Authors:  Giampiero Igli Baroncelli; Silvano Bertelloni; Federica Sodini; Giuseppe Saggese
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

7.  Iron excess upregulates SPNS2 mRNA levels but reduces sphingosine-1-phosphate export in human osteoblastic MG-63 cells.

Authors:  L Peltier; C Bendavid; T Cavey; M-L Island; M Doyard; P Leroyer; C Allain; M De Tayrac; M Ropert; O Loréal; P Guggenbuhl
Journal:  Osteoporos Int       Date:  2018-05-03       Impact factor: 4.507

Review 8.  Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease.

Authors:  A D Dede; G Trovas; E Chronopoulos; I K Triantafyllopoulos; I Dontas; N Papaioannou; S Tournis
Journal:  Osteoporos Int       Date:  2016-08-08       Impact factor: 4.507

9.  Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.

Authors:  Ersi Voskaridou; Ioannis Ntanasis-Stathopoulos; Athanasios Papaefstathiou; Dimitrios Christoulas; Maria Dimopoulou; Konstantina Repa; Athanasios Papatheodorou; Melpomeni Peppa; Evangelos Terpos
Journal:  Blood Adv       Date:  2018-11-13

10.  Zinc supplementation improves bone density in patients with thalassemia: a double-blind, randomized, placebo-controlled trial.

Authors:  Ellen B Fung; Janet L Kwiatkowski; James N Huang; Ginny Gildengorin; Janet C King; Elliott P Vichinsky
Journal:  Am J Clin Nutr       Date:  2013-08-14       Impact factor: 7.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.